AKR1C3-IN-9

SKU: orb1685565

Description

AKR1C3-IN-9 is a potent and selective AKR1C3 inhibitor with an IC50 of 8.92 nM. This compound has been shown to reverse doxorubicin resistance in breast cancer cell models, supporting its research use in studying chemoresistance mechanisms and as a potential therapeutic agent in oncology.

Research Area

Metabolism Research

Key Properties

• MW: 352.38
• Purity: 99.98% (May vary between batches)
• Formula: C₂₀H₂₀N₂O₄
• SMILES: CC1=C(C(=NO1)C)COC2=CC=CC=C2C(=O)NC3=CC=CC=C3OC
• Target: Reductase,NADPH
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.68 mM);DMSO:50 mg/mL (141.89 mM)

Bioactivity

• Target IC50:
  AKR1C3:8.92 nM
• In Vitro:
  AKR1C3-IN-9 (compound 24) (10-100 μM; 72 h and 96 h) shows a weak antiproliferative effect on three breast cancer cell lines (MDA-MB-231, MCF-7) with an inhibition range of up to 100 μM. AKR1C3-IN-9 (10 μM, 25 μM, 50 μM; 72 hours) in conjunction with 10-50 μM DOX synergistically inhibits the proliferation of MCF-7 cells. AKR1C3-IN-9 (10 μM; 8 d) with 50 μM DOX synergistically inhibits the proliferation and clonal survival of MCF-7/DOX cell lines, reinstating sensitivity to DOX .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AKR1C3

Compound Identifiers

PubChem CID

166449413